Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Bristol-Myers Squibb
Robert I Haddad; Kevin Harrington; Makoto Tahara; Robert L Ferris; Maura Gillison; Jerome Fayette; Amaury Daste; Piotr Koralewski; Bogdan Zurawski; Miren Taberna; Nabil F Saba; Milena Mak; Andrzej Kawecki; Gustavo Girotto; Miguel Angel Alvarez Avitia; Caroline Even; Joaquin Gabriel Reinoso Toledo; Alexander Guminski; Urs Müller-Richter; Naomi Kiyota; Mustimbo Roberts; Tariq Aziz Khan; Karen Miller-Moslin; Li Wei; Athanassios Argiris